Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia


Dr. Colombo on the Next Steps With Pembrolizumab in Cervical Cancer

October 28th 2021

Nicoletta Colombo, MD, PhD, discusses the next steps with pembrolizumab in cervical cancer.

Dr. Colombo on Practice-Changing KEYNOTE-826 Data in Metastatic Cervical Cancer

October 5th 2021

Nicoletta Colombo, MD, PhD, discusses efficacy achieved with the addition of pembrolizumab to chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer. 

The Future of Endometrial Cancer Treatment

June 4th 2021

Experts give insight on what they are looking forward to in the endometrial cancer space.

A Look at Surgical Innovations in EC

June 4th 2021

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Novel Targets of Interest in EC

June 4th 2021

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

Insight on Ongoing Trials in EC

June 4th 2021

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Incorporating Molecular Features into Choosing Adjuvant Therapy

June 4th 2021

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Therapeutic Sequencing in Endometrial Cancer

June 4th 2021

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

Managing AEs With Pembrolizumab and Lenvatinib

June 1st 2021

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer

June 1st 2021

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

A Discussion on the Study 309/KEYNOTE-775 Data

May 25th 2021

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Results from Study 309/KEYNOTE-775

May 25th 2021

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Study 309/KEYNOTE-775 Trial Design

May 18th 2021

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Therapeutic Approaches in Endometrial Cancer

May 18th 2021

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Biomarker Testing and Multidisciplinary Approaches in EC

May 11th 2021

Key opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.

Heterogeneity of Endometrial Cancer

May 11th 2021

Experts in gynecologic cancer discuss the heterogeneity of endometrial cancer..